Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation
- 15 March 2007
- journal article
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 66 (9), 1252-1254
- https://doi.org/10.1136/ard.2007.072397
Abstract
Correlation of serum trough infliximab levels and antibodies to infliximab (anti-infliximab) with clinical response in ankylosing spondylitis. In accordance with the international ASsessment in Ankylosing Spondylitis (ASAS) consensus statement, patients were treated with infliximab (5 mg/kg) every 6 weeks after a starting regimen. Preinfusion sera were collected at baseline, 24 and 54 weeks. At every visit, the 20% improvement response (ASAS-20) was assessed and laboratory tests performed. 24 of the 38 (63%) patients fulfilled ASAS-20 response criteria after 24 weeks of treatment and 21 (53%) after 54 weeks. After 54 weeks, 11 (29%) patients showed undetectable serum trough infliximab levels and detectable anti-infliximab; six of these patients developed an infusion reaction. Anti-infliximab was found significantly more often (p = 0.04) in ASAS-20 non-responders compared with responders at week 54. Serum trough infliximab levels were significantly (p<0.0001) lower in patients with (mean 0.02 mg/l) than in those without (12.7 mg/l) anti-infliximab. In ankylosing spondylitis, high levels of serum trough infliximab correlated with a good clinical response. Detection of anti-infliximab within 54 weeks is associated with undetectable serum trough infliximab levels, reduced response to treatment and increased risk of developing an infusion reaction.Keywords
This publication has 12 references indexed in Scilit:
- No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trialAnnals Of The Rheumatic Diseases, 2007
- Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formationAnnals Of The Rheumatic Diseases, 2006
- Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritisArthritis & Rheumatism, 2006
- Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo‐controlled trial (ASSERT)Arthritis & Rheumatism, 2005
- International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitisAnnals Of The Rheumatic Diseases, 2003
- Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's DiseaseNew England Journal of Medicine, 2003
- The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: Results from ATTRACT, a multicenter, randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2002
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002
- Mouse/human chimeric IgGl and IgG4 antibodies directed to the house dust mite allergen Der p 2: use in quantification of allergen specific IgGClinical and Experimental Allergy, 1997
- Evaluation of Diagnostic Criteria for Ankylosing SpondylitisArthritis & Rheumatism, 1984